mtDNA Damage in Alzheimer's Disease (AD)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Alzheimer Disease
- Sponsor
- Duke University
- Enrollment
- 21
- Locations
- 1
- Primary Endpoint
- Biological marker of Alzheimer's disease
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
Currently, no cures or disease modifying therapies exist for Alzheimer's disease (AD). This is partially due to the inability to detect the disease before it has progressed to a stage where there are clinical manifestations. The identification and validation of high throughput biomarkers to measure disease progression (as well as identify pre-clinical disease onset) is critical to the development of disease-modifying or even preventative therapies. In this study, we are testing a blood biomarker for stratification of Alzheimer's disease patients and healthy volunteers. This study may lead to future blood tests that may help earlier diagnosis of Alzheimer's disease and detect the disease progression.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Alzheimer's Disease Patients:
- •50 years and older
- •AD patient who is seen at the Memory Disorders Clinic
- •AD diagnosis
- •Non smoking
- •No cancer treatment in the last 5 years
- •Informed consent from the patient or the patient's legally authorized representative (LAR)
- •Patient and/or LAR able to read and speak English
- •Healthy Control Participants:
- •50 years and older
Exclusion Criteria
- •Alzheimer's Disease Patients:
- •Known additional neurological disease
- •Healthy Control Participants:
- •Neurological degenerative diseases (such as Parkinson's, Alzheimer's or Huntington's)
Outcomes
Primary Outcomes
Biological marker of Alzheimer's disease
Time Frame: Day 1
Test for blood biological marker of Alzheimer's disease, mtDNA damage